Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Novartis' Sandoz unit has spun off its antibiotic R&D operations into a new company, Nabriva, which will be fueled by $50 million in financing from Nomura Phase4 Ventures, Global Life Science Ventures, the Wellcome Trust, HBM Partners, and Novartis' venture capital arm. Sandoz says the R&D operation didn't fit with its focus on generics. Nabriva will develop small-molecule antibiotics for use against community and hospital infections. Its pipeline of antibacterial drugs includes three late preclinical projects and one product about to enter Phase I trials.
This article has been sent to the following recipient: